Entry into a Material Definitive Agreement

APEX Tech Acquisition Inc. (8-K) — October 20, 2026

Business context and reporting period

This 8-K reports APEX’s entry into a merger agreement with Korai Flix, Inc. on October 20, 2026. It describes a proposed business combination, not quarterly or annual operating results. APEX is a special purpose acquisition company; the filing refers to Korai’s platform and identifies pharmaceutical-industry risks but does not provide a detailed business description.

Before closing, APEX is to redomicile from the Cayman Islands to Delaware. At closing, it expects to change its name to “Krflix Group, Inc.” or another mutually agreed name. Korai would survive as a wholly owned subsidiary.

Transaction economics and financial information

  • Merger consideration: $3.5 billion, payable entirely in New Korai common stock valued at $10 per share. This implies 350 million merger consideration shares, allocated between Class A and Class B based on Korai’s outstanding share-class proportions immediately before closing.
  • Additional shares: Korai’s representative is to receive 35,000 New Korai Class A shares upon completion of the merger.
  • Financial performance: The 8-K does not report revenue, profit, cash flow, margins, debt, or liquidity results, nor provide comparable-period financial statements. It is not possible to assess operating performance from this filing.
  • Closing financial thresholds: After any APEX public-shareholder redemptions, APEX must have at least $5,000,001 in net tangible assets. Korai must have consolidated net assets of at least $100 million for the calendar quarter immediately before closing.

Material terms, changes, and conditions

  • The transaction requires approval by both APEX shareholders and Korai stockholders, an effective Form S-4 registration statement, regulatory and other required consents, and NYSE listing approval for the New Korai Class A shares, among other conditions.
  • APEX has a due-diligence review period through 5:00 p.m. on December 19, 2026, and may terminate the agreement by written notice before that period expires.
  • Korai must have at least 20 million registered platform users at closing. APEX also must receive a fairness opinion concluding the transaction is financially fair to APEX shareholders.
  • The post-closing board is planned to have five members: one designated by APEX and four by Korai, with at least two of Korai’s designees qualifying as independent under NYSE rules.
  • Significant Korai stockholders agreed to vote in favor of the transaction and are subject to transfer restrictions. Their merger consideration shares are generally locked up for six months after closing; bonus shares are generally locked up for twelve months.
  • The agreement may be terminated in specified circumstances, including failure to close by October 19, 2027, subject to a possible extension tied to APEX’s business-combination deadline; failure to obtain either shareholder approval; or certain uncured breaches or final prohibitory orders.

Outlook, risks, and unusual items

No operating or financial guidance is provided. Completion remains conditional, and the filing highlights risks including shareholder redemptions or lack of approvals, unsatisfactory due diligence, failure to meet closing conditions or listing standards, regulatory and legal proceedings, transaction costs, disruption to Korai’s operations, and uncertainty in the competitive and changing pharmaceutical industry. The merger agreement’s representations and warranties do not survive closing, and it provides no post-closing indemnification for their breach.

Important facts for investors to verify

  • Review the forthcoming Form S-4 and proxy statement/prospectus, including Korai’s financial statements, business details, risk factors, and transaction assumptions.
  • Confirm the final share count and Class A/Class B allocation, and assess dilution from APEX securities, redemptions, and other equity arrangements.
  • Monitor shareholder approvals, redemptions, trust-account proceeds, and whether APEX meets the $5,000,001 net tangible asset condition.
  • Verify Korai’s net assets and registered-user count against the contractual closing thresholds, along with the fairness opinion and required consents.
  • Track due-diligence findings, the December 19, 2026 review deadline, NYSE listing approval, and any changes to the expected closing timeline or terms.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.